Physician profile
Philip Wrotslavsky
NPI 1558403493
$269,422.48
in general payments reported to CMS, 2019-2025
47 companies · $3,069 in 2025
The $3,069 reported for 2025 was more than what 94% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $5,878 · 2021: $54K · 2022: $41K · 2023: $83K · 2024: $60K · 2025: $3,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $72K · Travel and Lodging: $34K · Consulting Fee: $26K · Acquisitions: $9,661 · Food and Beverage: $4,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $71,658.13 |
| Travel and Lodging | $34,081.56 |
| Consulting Fee | $26,322.44 |
| Acquisitions | $9,660.50 |
| Food and Beverage | $4,161.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $79,285.17 | 2020-2025 | Nuzyra |
| Orthofix Medical, INC. | $72,424.25 | 2019-2025 | Truelok, Galaxy Fixation System, Tl-Hex Truelok Hexapod System |
| Kci USA, INC. | $49,819.28 | 2019-2023 | V.A.C. Dermatac, Activ.A.C., Promogran Prisma |
| Abbvie INC. | $26,295.19 | 2021-2024 | Dalvance |
| Solventum Corporation | $23,494.36 | 2024-2025 | Prevena, V.A.C. Dermatac, Activ.A.C. |
| Zimmer Biomet Holdings, INC. | $9,769.03 | 2019-2023 | Archimis |
| Melinta Therapeutics, LLC | $4,473.64 | 2022-2023 | Kimyrsa, Orbactiv |
| Extremity Medical | $1,115.57 | 2022-2023 | Io Fix |
| Zyla Life Sciences, INC. | $379.52 | 2019-2020 | |
| Stryker Corporation | $274.40 | 2019-2025 | Prostep, Augment Injectable |
| Withings, INC. | $221.75 | 2025 | |
| Avitus Orthopaedics, INC. | $172.80 | 2019 | |
| Biotissue Holdings INC. | $144.00 | 2022-2024 | |
| Mimedx Group, INC. | $141.97 | 2024 | |
| Smith+Nephew, INC. | $126.25 | 2020-2025 | Bone Anchors With Arthroscopic Delivery System, Taylor Spatial Frame |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Wrotslavsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.